Role of Medical Imaging in Cancers, / Volume 2.
The issue of Cancers Journal entitled “Role of Medical Imaging in Cancers” presents a detailed summary of evidences about molecular imaging, including the role of computed tomography (CT), magnetic resonance imaging (MRI), single photon emission tomography (SPET) and positron emission tomography (PE...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (228 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 06452nam-a2202029z--4500 | ||
|---|---|---|---|
| 001 | 993545511204498 | ||
| 005 | 20231214133513.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202105s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000042761 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68463 | ||
| 035 | |a (EXLCZ)995400000000042761 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Fanti, Stefano |4 edt | |
| 245 | 1 | 0 | |a Role of Medical Imaging in Cancers, |n Volume 2. |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (228 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The issue of Cancers Journal entitled “Role of Medical Imaging in Cancers” presents a detailed summary of evidences about molecular imaging, including the role of computed tomography (CT), magnetic resonance imaging (MRI), single photon emission tomography (SPET) and positron emission tomography (PET) or PET/CT or PET/MR imaging in many type of tumors (i.e. sarcoma, prostate, breast and others), motivating the role of these imaging modalities in different setting of disease and showing the recent developments, in terms of radiopharmaceuticals, software and artificial intelligence in this field. The collection of articles is very useful for many specialists, because it has been conceived for a multidisciplinary point of view, in order to drive to a personalized medicine. | ||
| 546 | |a English | ||
| 650 | 0 | |a Medicine. | |
| 653 | |a positron emission tomography | ||
| 653 | |a head and neck neoplasms | ||
| 653 | |a neovascularization | ||
| 653 | |a pathologic | ||
| 653 | |a PET/CT | ||
| 653 | |a urothelial carcinoma | ||
| 653 | |a bladder cancer | ||
| 653 | |a upper tract urothelial carcinoma | ||
| 653 | |a survival | ||
| 653 | |a PET | ||
| 653 | |a PSMA | ||
| 653 | |a prostate | ||
| 653 | |a DCFPyL | ||
| 653 | |a DCFBC | ||
| 653 | |a PSMA-1007 | ||
| 653 | |a ovarian cancer | ||
| 653 | |a relapse | ||
| 653 | |a SUVmax | ||
| 653 | |a targeted therapy | ||
| 653 | |a prognosis | ||
| 653 | |a soft tissue sarcoma (STS) | ||
| 653 | |a pazopanib | ||
| 653 | |a dynamic 18F-FDG PET/CT | ||
| 653 | |a SUV | ||
| 653 | |a two-tissue compartment model | ||
| 653 | |a magnetic resonance imaging | ||
| 653 | |a machine learning | ||
| 653 | |a diffusion | ||
| 653 | |a perfusion | ||
| 653 | |a texture analysis | ||
| 653 | |a squamous cell carcinoma of the head and neck | ||
| 653 | |a diffusion-weighted imaging | ||
| 653 | |a malignant pleural mesothelioma | ||
| 653 | |a pleural dissemination | ||
| 653 | |a empyema | ||
| 653 | |a pleural effusion | ||
| 653 | |a mCRPC | ||
| 653 | |a SPECT/CT | ||
| 653 | |a Computer-assisted diagnosis | ||
| 653 | |a XOFIGO | ||
| 653 | |a Therapy response assessment | ||
| 653 | |a circulating miRNAs | ||
| 653 | |a breast cancer | ||
| 653 | |a imaging parameters | ||
| 653 | |a PET/MRI | ||
| 653 | |a biomarkers | ||
| 653 | |a triple negative breast cancer | ||
| 653 | |a VCAM-1 | ||
| 653 | |a SPECT imaging | ||
| 653 | |a sdAbs | ||
| 653 | |a Hounsfield unit | ||
| 653 | |a computed tomography | ||
| 653 | |a adipose tissue | ||
| 653 | |a precision oncology | ||
| 653 | |a FDG-PET/CT | ||
| 653 | |a PERCIST | ||
| 653 | |a metastatic breast cancer | ||
| 653 | |a prostate cancer | ||
| 653 | |a 18F-FACBC | ||
| 653 | |a recurrence | ||
| 653 | |a meta-analysis | ||
| 653 | |a review | ||
| 653 | |a meningioma | ||
| 653 | |a somatostatin receptor | ||
| 653 | |a neuroimaging | ||
| 653 | |a radionuclide therapy | ||
| 653 | |a breast | ||
| 653 | |a imaging | ||
| 653 | |a marker | ||
| 653 | |a radiomics | ||
| 653 | |a Yin Yang 1 | ||
| 653 | |a PDAC | ||
| 653 | |a Mesothelin | ||
| 653 | |a noninvasive imaging | ||
| 653 | |a receptor status | ||
| 653 | |a molecular imaging | ||
| 653 | |a nuclear medicine | ||
| 653 | |a guidelines | ||
| 653 | |a overutilization | ||
| 653 | |a epistemology | ||
| 653 | |a consensus | ||
| 653 | |a mantle cell lymphoma | ||
| 653 | |a 18F-FDG PET/CT | ||
| 653 | |a Deauville criteria | ||
| 653 | |a Radium-223 | ||
| 653 | |a FDG | ||
| 653 | |a castrate resistant prostate cancer | ||
| 653 | |a programmed cell death 1 receptor | ||
| 653 | |a diagnostic imaging | ||
| 653 | |a CTLA-4 Antigen | ||
| 653 | |a Immunotherapy | ||
| 653 | |a Adoptive | ||
| 653 | |a radioactive tracers | ||
| 653 | |a radionuclide imaging | ||
| 653 | |a CD8-Positive T-Lymphocytes | ||
| 653 | |a PI-RADS | ||
| 653 | |a diffusion kurtosis imaging | ||
| 653 | |a dynamic contrast-enhanced magnetic resonance imaging | ||
| 653 | |a 68Gallium-PSMA PET/CT | ||
| 653 | |a prostate-specific-antigen | ||
| 653 | |a PSA kinetics thresholds | ||
| 653 | |a biochemical recurrence | ||
| 653 | |a optimal cutoff level | ||
| 653 | |a non-small-cell lung cancer | ||
| 653 | |a circulating tumor cells | ||
| 653 | |a immunotherapy | ||
| 653 | |a response to treatment | ||
| 653 | |a head and neck cancer | ||
| 653 | |a HPV | ||
| 653 | |a EBV | ||
| 653 | |a p16 | ||
| 653 | |a Molecular imaging | ||
| 653 | |a miRNA expression | ||
| 653 | |a radiogenomics | ||
| 653 | |a radiomic | ||
| 653 | |a diagnosis | ||
| 653 | |a biomarker | ||
| 653 | |a glioblastoma | ||
| 653 | |a radiation therapy | ||
| 653 | |a MRI | ||
| 653 | |a diffusion tensor imaging | ||
| 653 | |a Hodgkin lymphoma | ||
| 653 | |a diffuse large B-cell lymphoma | ||
| 653 | |a staging | ||
| 653 | |a response assessment | ||
| 653 | |a locally advanced cervical cancer | ||
| 653 | |a concurrent chemoradiotherapy | ||
| 653 | |a treatment response | ||
| 653 | |a follow up | ||
| 653 | |a cystic tumor | ||
| 653 | |a International Consensus Guidelines | ||
| 653 | |a intraductal papillary mucinous neoplasms | ||
| 653 | |a pancreatic neoplasms | ||
| 653 | |a PD-1 | ||
| 653 | |a PD-L1 | ||
| 653 | |a response to therapy | ||
| 653 | |a NSCLC | ||
| 653 | |a positron-emission tomography | ||
| 653 | |a single-photon emission computed tomography | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a gold nanoparticle | ||
| 653 | |a heat shock protein 70 | ||
| 653 | |a spectral-CT | ||
| 776 | |z 3-0365-0206-8 | ||
| 776 | |z 3-0365-0207-6 | ||
| 700 | 1 | |a Evangelista, Laura |4 edt | |
| 700 | 1 | |a Fanti, Stefano |4 oth | |
| 700 | 1 | |a Evangelista, Laura |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:56:08 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337935960004498&Force_direct=true |Z 5337935960004498 |b Available |8 5337935960004498 | ||